afap1l1 Antibody

What is AFAP1L1 and what are its primary cellular functions?

AFAP1L1 is a 768 amino acid adaptor protein that plays a crucial role in cellular signaling and actin organization. It functions by linking signaling molecules to actin filaments, which is vital for the formation of larger signaling complexes essential for Src kinase activation in response to various cellular signals . AFAP1L1 is one of three members in the AFAP1 family of adaptor proteins and, while sharing structural similarities with AFAP1, is thought to have unique functions . Notably, AFAP1L1 is phosphorylated upon DNA damage, likely by ATM or ATR kinases, highlighting its importance in cellular stress responses . The protein exists in at least four isoforms due to alternative splicing, contributing to its functional diversity .

What types of AFAP1L1 antibodies are available for research applications?

Several types of AFAP1L1 antibodies are available for research:

How does AFAP1L1 differ from other AFAP family proteins?

While AFAP1L1 shares structural similarities with AFAP1, including actin-binding properties and a role in cytoskeleton arrangement, it demonstrates unique functions . Unlike other AFAP family members, AFAP1L1 specifically colocalizes with cortactin and vinculin in the ringed structure of invadopodia . Research indicates that AFAP1L1 has a distinct role in cell invasion processes, particularly in the context of cancer progression, where it modulates cell shape and motility while inhibiting anoikis . Most antibodies against AFAP1L1 are designed not to cross-react with other AFAP family members, allowing for specific targeting of this protein .

What are the optimal protocols for using AFAP1L1 antibodies in Western blotting?

When using AFAP1L1 antibodies for Western blotting, researchers should consider the following protocol elements:

• Sample preparation: AFAP1L1 has been successfully detected in various cancer cell lines, particularly colorectal cancer cells. Whole cell lysates are typically sufficient for detection .

• Antibody dilution: Recommended dilutions vary by manufacturer:

  • Proteintech's antibody (23909-1-AP): 1:500-1:1000

  • Other antibodies may require optimization, but typically range from 1:500 to 1:2000

• Expected molecular weight: Although the calculated molecular weight is 86 kDa, observed bands typically appear between 68-86 kDa depending on the isoform and post-translational modifications .

• Controls: When analyzing AFAP1L1 expression in cancer tissues, adjacent normal tissue serves as an effective negative control, as AFAP1L1 is significantly upregulated in several cancer types compared to normal tissues .

• Storage and handling: Most AFAP1L1 antibodies should be stored at -20°C for long-term stability (up to one year). For shorter periods (up to three months), 4°C storage is acceptable. Repeated freeze-thaw cycles should be avoided .

How can AFAP1L1 antibodies be effectively utilized in immunofluorescence studies?

For optimal immunofluorescence (IF) results with AFAP1L1 antibodies:

• Cellular localization: AFAP1L1 localizes to the ringed structure of invadopodia along with vinculin . When conducting IF studies, co-staining with vinculin or cortactin antibodies can help confirm proper localization and function.

• Fixation methods: Paraformaldehyde fixation (4%) for 15-20 minutes at room temperature is commonly used for preserving AFAP1L1 localization in cellular structures.

• Permeabilization: A gentle permeabilization using 0.1-0.2% Triton X-100 is recommended to maintain the integrity of cytoskeletal structures while allowing antibody access.

• Antibody selection: For co-localization studies, select AFAP1L1 antibodies raised in different host species than antibodies against potential binding partners (e.g., rabbit anti-AFAP1L1 with mouse anti-vinculin).

• Confocal microscopy: Due to AFAP1L1's association with specific subcellular structures, confocal microscopy is preferable for accurately resolving its localization patterns.

What approaches can be used to validate AFAP1L1 antibody specificity?

Validation of AFAP1L1 antibody specificity is critical for reliable research outcomes. Recommended approaches include:

• siRNA knockdown: Transfection with siRNA against AFAP1L1 should result in decreased signal intensity compared to scrambled siRNA controls. This has been demonstrated effectively in colorectal cancer models .

• Overexpression systems: Complementary to knockdown, overexpression of tagged AFAP1L1 should show increased signal and colocalization with the antibody staining.

• Peptide competition assays: Pre-incubation of the antibody with blocking peptides corresponding to the immunogen should abolish specific staining in Western blot and immunostaining applications .

• Cross-reactivity testing: While most AFAP1L1 antibodies are predicted not to cross-react with other AFAP family members, validation across multiple cell types expressing different levels of AFAP1L1 can confirm specificity .

• Multiple antibody comparison: Validating results using antibodies targeting different epitopes of AFAP1L1 can significantly increase confidence in specificity.

How can AFAP1L1 antibodies be used to investigate protein-protein interactions?

AFAP1L1 has been identified as an interacting partner with vinculin and cortactin . To investigate these and other potential interactions:

• Co-immunoprecipitation (Co-IP): AFAP1L1 antibodies such as the Santa Cruz D-7 monoclonal antibody have been successfully used for immunoprecipitation . For Co-IP:

  • Use mild lysis buffers to preserve protein-protein interactions

  • Pre-clear lysates to reduce non-specific binding

  • Include appropriate controls (IgG control, reverse IP)

• Proximity ligation assay (PLA): This technique can visualize and quantify specific protein interactions in situ with spatial resolution.

• FRET/BRET analysis: For studying dynamic interactions, fluorescence or bioluminescence resonance energy transfer techniques can be employed using tagged AFAP1L1.

• GST pull-down assays: To confirm direct interactions, in vitro binding assays using GST-tagged AFAP1L1 domains can identify specific binding regions.

• Yeast two-hybrid screening: For discovering novel AFAP1L1 binding partners, Y2H screening using AFAP1L1 as bait can be effective.

What are the challenges in detecting endogenous AFAP1L1 in different tissue types?

Researchers face several challenges when detecting endogenous AFAP1L1:

• Variable expression levels: AFAP1L1 is highly expressed in breast, colon, and brain tissues but may be expressed at lower levels in other tissues, requiring optimization of detection methods .

• Isoform variation: With at least four known isoforms, different antibodies may detect different subsets of AFAP1L1 variants, leading to apparently discrepant results .

• Signal amplification: For tissues with low AFAP1L1 expression, signal amplification techniques such as tyramide signal amplification (TSA) may be necessary.

• Background reduction: Optimizing blocking conditions (3-5% BSA or normal serum from the same species as the secondary antibody) can improve signal-to-noise ratio.

• Tissue-specific fixation: Different tissues may require modified fixation protocols to preserve AFAP1L1 epitopes while maintaining tissue morphology.

How can hypoxia-induced regulation of AFAP1L1 be effectively studied using antibody-based approaches?

Recent research has identified hypoxia as a regulator of AFAP1L1 expression . To study this relationship:

• Hypoxia chamber experiments: Culture cells under controlled hypoxic conditions (1-2% O2) at different time points, followed by Western blotting to track AFAP1L1 protein levels.

• HIF-1α/HIF-2α co-localization: Dual immunofluorescence with AFAP1L1 and HIF antibodies can reveal spatial relationships under hypoxic conditions.

• ChIP assays: Using HIF-1α/HIF-2α antibodies for chromatin immunoprecipitation followed by PCR of the AFAP1L1 promoter region containing hypoxic response elements (HREs) can confirm direct regulation .

• Luciferase reporter assays: As demonstrated in search result , transfecting cells with luciferase reporter constructs containing wild-type or mutated HRE promoter regions of AFAP1L1 can quantify hypoxia-dependent transcriptional activation.

• Pharmacological HIF stabilization: Using HIF stabilizers like CoCl2 or deferoxamine can mimic hypoxia and allow for more controlled experimental conditions when studying AFAP1L1 regulation.

How should researchers interpret AFAP1L1 expression patterns in cancer versus normal tissues?

Based on research findings:

• Quantitative assessment: In colorectal cancer studies, AFAP1L1 gene expression was upregulated in tumor tissues more than twofold higher than in adjacent normal mucosa in 69% (42/61) of cases . When assessing AFAP1L1 levels:

  • Consider setting a threshold (e.g., log ratio >1.0 as used in CRC studies)

  • Compare expression across multiple patient samples and cancer stages

• Prognostic value: Multivariate analysis has revealed AFAP1L1 as an independent and significant factor for recurrence in rectal cancers . Researchers should correlate AFAP1L1 expression with:

  • Lymph node metastasis status

  • Patient survival data

  • Tumor invasiveness parameters

• Histological correlation: Higher AFAP1L1 expression may correlate with specific histological features, requiring careful assessment of tumor heterogeneity.

• Stage-specific changes: Consider analyzing AFAP1L1 expression across different cancer stages (I-IV) to identify potential stage-specific roles.

• Integration with other markers: Combining AFAP1L1 expression data with other prognostic markers can provide more comprehensive prognostic information, particularly for rectal cancers .

What cellular morphological changes correlate with AFAP1L1 expression patterns?

AFAP1L1 expression has been associated with specific cellular morphological changes:

• Cell shape alteration: AFAP1L1-transduced colorectal cancer cells exhibit a more rounded shape compared to controls .

• Actin cytoskeleton rearrangement: As an actin-binding protein, AFAP1L1 modifies actin filament organization, which can be visualized using phalloidin staining in immunofluorescence studies.

• Invadopodia formation: AFAP1L1 localizes to ringed structures of invadopodia along with vinculin, suggesting a role in these invasion-associated structures .

• Cell motility changes: Increased AFAP1L1 expression correlates with enhanced cell motility on planar substrates .

• Anoikis resistance: Cells overexpressing AFAP1L1 demonstrate resistance to anoikis, which can be assessed through suspension culture viability assays .

How can contradictory results in AFAP1L1 research be reconciled?

When facing contradictory results:

• Antibody epitope differences: Different antibodies targeting distinct regions of AFAP1L1 may yield different results depending on post-translational modifications, protein interactions, or isoform expression.

• Cell type specificity: AFAP1L1 function may vary across cell types; for example, its role in colorectal cancer cells may differ from its function in breast cancer or normal cells.

• Experimental conditions: Hypoxia significantly affects AFAP1L1 expression ; therefore, oxygen levels during experiments may influence results.

• Isoform-specific effects: With four known isoforms, specific experimental conditions might favor one isoform over others, potentially leading to seemingly contradictory functional outcomes.

• Interaction partners: The presence or absence of key AFAP1L1 interacting partners like vinculin or cortactin in different experimental systems may affect observed functions.

What experimental designs would best evaluate AFAP1L1 as a therapeutic target?

Based on current knowledge of AFAP1L1:

• In vivo siRNA studies: Local administration of siRNA against AFAP1L1 has shown significant suppression of tumor growth in xenograft models , suggesting experimental designs should include:

  • Dose-response studies for siRNA/shRNA delivery

  • Comparison of different delivery methods (local vs. systemic)

  • Combination with standard chemotherapeutics

• Small molecule inhibitor development: Design screening assays for compounds that:

  • Disrupt AFAP1L1-vinculin interactions

  • Inhibit AFAP1L1 phosphorylation

  • Alter AFAP1L1 subcellular localization

• Antibody-drug conjugates: Evaluate the potential of AFAP1L1 antibodies as delivery vehicles for cytotoxic agents, particularly in colorectal cancers with high AFAP1L1 expression.

• Combinatorial approaches: Test AFAP1L1 targeting in combination with:

  • Hypoxia-targeting therapies

  • Actin cytoskeleton disruptors

  • Src kinase inhibitors

• Patient-derived xenograft models: Establish PDX models from patients with varying AFAP1L1 expression levels to assess targeting efficacy in more clinically relevant settings.

How might AFAP1L1 antibodies be optimized for detecting hypoxia-induced changes in tumor microenvironments?

For studying hypoxia-related AFAP1L1 changes:

• Dual immunohistochemistry protocols: Optimize protocols for simultaneous detection of AFAP1L1 and hypoxia markers (HIF-1α, CA9, GLUT1) in tumor sections.

• Proximity to vasculature: Analyze AFAP1L1 expression relative to distance from blood vessels in tumor sections to correlate with hypoxic gradients.

• Live cell imaging: Develop fluorescently tagged antibody fragments or nanobodies against AFAP1L1 for real-time monitoring of expression changes during hypoxia-reoxygenation cycles.

• Phospho-specific antibodies: Develop antibodies specifically targeting hypoxia-induced phosphorylation sites on AFAP1L1 to distinguish activated forms.

• 3D tumor spheroid models: Utilize 3D culture systems with oxygen gradients to better replicate in vivo tumor conditions when studying AFAP1L1 regulation.

What methodological approaches would best characterize the four AFAP1L1 isoforms and their distinct functions?

To differentiate between AFAP1L1 isoforms:

• Isoform-specific antibodies: Develop antibodies targeting unique regions of each AFAP1L1 isoform to allow specific detection.

• RT-PCR primer design: Design primers spanning exon-exon junctions specific to each isoform for quantitative analysis of isoform-specific mRNA expression.

• Mass spectrometry approaches: Use targeted proteomic approaches to identify and quantify specific peptides unique to each isoform.

• CRISPR-based isoform editing: Selectively modify specific exons to generate cell lines expressing only certain isoforms for functional comparison.

• Isoform-specific interactome analysis: Perform IP-MS studies with isoform-specific tags to identify unique binding partners for each variant.